EGFR/Ras-induced CCL20 production modulates the tumour microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• The epidermal growth factor receptor (EGFR)/Ras signaling pathway activation in tumor cells influences the tumor microenvironment via chemokine production.
• This study investigates the role of CCL20, a key chemokine, in tumor progression and angiogenesis.

Purpose of the Study:

• To analyze the effects of EGFR/Ras on CCL20 expression and translation in epithelial cancers.
• To investigate the role of CCL20 in tumor-associated vascularization and endothelial cell migration.
• To evaluate the therapeutic potential of targeting the CCL20-CCR6 axis.

Main Methods:

• Quantitative reverse transcription PCR (RT-qPCR) and ELISA were used to analyze CCL20 expression in cancer cell lines and tissues.
• Immunohistochemistry was employed to verify CCL20 production in tumors and correlate it with clinical data.
• Chemotaxis assays and studies in CCR6-deficient mice were conducted to assess CCL20's effects on endothelial cells and tumor vascularization.

Main Results:

• EGFR/Ras-induced CCL20 production facilitates tumor progression, correlating with advanced stage, lymph node metastasis, and reduced patient survival.
• Microvascular endothelial cells express the CCL20 receptor CCR6, and CCR6 signaling promotes angiogenesis.
• CCR6 deficiency in stromal cells significantly reduced tumor growth and vascularization in mice.

Conclusions:

• The CCL20-CCR6 chemokine axis is a novel target for modulating the tumor microenvironment.
• Targeting this axis presents an innovative multimodal strategy for cancer therapy.